A 54-year-old male presented to our hospital because of upper abdominal pain. The patient weighed 65 kg, his height was 167 cm, and the standard liver volume (SLV) was 1231 mL, which was calculated based on the Urata formula. Laboratory examination ( Table 1 ) showed alpha fetoprotein (AFP) >60500 ng/mL, total bilirubin (TBil) 20.4 mumol/L, direct bilirubin (DBil) 7.1 mumol/L, alanine transaminase (ALT) 69 U/L, and hepatitis B surface antigen (HBsAg) (+). Abdominal enhanced computed tomography (CT) indicated liver cirrhosis, a 14.9 cm x 11.8 cm mass located in the right liver and a 1.5 cm x 1.0 cm mass located in the left liver both with heterogeneous rapid enhancement of the mass in the arterial phase ( Figure 1A ). The patient was diagnosed with chronic hepatitis B from childhood and had regular antiviral therapy while finding the masses in the liver. The clinical diagnosis was HCC with BCLC-B stage. According to the BCLC strategy, transarterial chemoembolization (TACE) and a combination of the targeted drug (lenvatinib, 8 mg once a day) and ICIs (camrelizumab, 200 mg every three weeks) were performed ( Figure 1F ). After two courses of TACE and five cycles of immunotherapy, abdominal enhanced CT showed that the range of enhancement was significantly smaller than before. Although the diameter of the lesion was slightly smaller, the lesion reached partial response (PR; i.e., >30% decrease in the sum of diameters of viable (enhancing) target lesions) according to modified Response Evaluation Criteria Solid Tumours (mRECIST). Laboratory examination before the surgery showed AFP 167.0 ng/mL, TBil 14.6 mumol/L, DBil 5.9 mumol/L, aspartic transaminase (AST) 41 U/L, and ALT 37 U/L. The volume of FLR was 475 mL, as calculated by abdominal CT ( Figure 1B ). An insufficient FLR could be linked to a high risk of postoperative liver failure after first-stage resection. After having obtained the consent of the patient and his family, the first stage of ALPPS and resection of the left lesion by laparoscopy was performed three months after the first course of TACE. A postoperative liver function test (LFT) indicated TBil 13.3 mumol/L, DBil 5.5 mumol/L, and ALT 303 U/L. Liver function improved after liver protection therapy. Twenty-one days after the first-stage surgery, abdominal CT indicated that the FLR increased to 576 mL ( Figure 1C ), and the rate of FLR/SLV was 46.8%, which could meet the needs of the body. The second stage of ALPPS was completed, and the TBil, DBil and ALT were 30.6 mumol/L, 13.3 mumol/L and 182 U/L, respectively, on the first day after surgery. Changes in liver function are shown in  Figure 1E . The FLR was 708 mL ( Figure 1D ), and the patient was discharged 7 days after second-stage ALPPS. A pathology report demonstrated a mass in the left liver with moderately differentiated HCC and a mass in the right liver with extensive haemorrhage and necrosis and no clear residual tumour cells, which reached pathological complete response (pCR). The systemic therapy was restored two months after ALPPS with the same regimen as before in the follow-up clinic. The follow-up examination showed no recurrence on imaging and sufficient FLR on that day.